Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro
A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro

A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.

A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.

B.1.351
Another Potentially Immunity-Evading SARS-CoV-2 Variant Detected
Another Potentially Immunity-Evading SARS-CoV-2 Variant Detected
Asher Jones | Feb 16, 2021
B.1.525 shares a mutation with the B.1.351 variant first detected in South Africa that seems to allow the virus to dodge the immune system.
SARS-CoV-2 with Genomic Deletions Escapes an Antibody
SARS-CoV-2 with Genomic Deletions Escapes an Antibody
Abby Olena | Feb 16, 2021
Researchers identify deletions in the N-terminal domain of the spike protein that allow the coronavirus to avoid antibody neutralization and that may contribute to the emergence of new variants.
Side-by-Side Comparisons of Important SARS-CoV-2 Variants
Side-by-Side Comparisons of Important SARS-CoV-2 Variants
Katarina Zimmer | Jan 26, 2021
Here’s our brief guide to the most noteworthy mutations in the novel coronavirus.
Special report
A Guide to Emerging SARS-CoV-2 Variants
A Guide to Emerging SARS-CoV-2 Variants
Katarina Zimmer | Jan 26, 2021
Scientists across the world are closely tracking the spread of mutations in the coronavirus and investigating whether they could render current vaccines less effective.
Moderna Developing Booster Shot for New Virus Variant B.1.351
Moderna Developing Booster Shot for New Virus Variant B.1.351
Asher Jones | Jan 25, 2021
New data suggest that the company’s approved COVID-19 vaccine protects against different virus variants, but could be less effective against the one that originated in South Africa.